Literature DB >> 16460914

Signaling through ERBB receptors: multiple layers of diversity and control.

Carmen M Warren1, Ralf Landgraf.   

Abstract

The four known ERBB receptors in humans are involved in a broad range of cellular responses, and their deregulation is a significant aspect in a large number of disease states. However, their mechanism of action and modes of control are still poorly understood. This is largely due to the fact that the control of ERBB activity is a multilayered process with significant differences between the various ERBB members. In contrast to other receptor tyrosine kinases, the kinase domain of EGFR (ERBB1) does not require phosphorylation for activation. Consequently, the overall activation state of the receptor is controlled by constant balancing of activity favoring and activity suppressing actions within the receptor molecule. Influences of the membrane microenvironment and context dependent interactions with varying sets of signaling partners are superimposed on this system of intramolecular checks and balances. We will discuss current models of the control of ERBB signaling with an emphasis on the multilayered nature of activation control and aspects that give rise to diversity between ERBB receptors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16460914     DOI: 10.1016/j.cellsig.2005.12.007

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  53 in total

Review 1.  Structure elucidation of dimeric transmembrane domains of bitopic proteins.

Authors:  Eduard V Bocharov; Pavel E Volynsky; Konstantin V Pavlov; Roman G Efremov; Alexander S Arseniev
Journal:  Cell Adh Migr       Date:  2010-05-01       Impact factor: 3.405

2.  Mechanistic and signaling analysis of Muc4-ErbB2 signaling module: new insights into the mechanism of ligand-independent ErbB2 activity.

Authors:  Goldi A Kozloski; Coralie A Carothers Carraway; Kermit L Carraway
Journal:  J Cell Physiol       Date:  2010-09       Impact factor: 6.384

Review 3.  Structure, evolution, and biology of the MUC4 mucin.

Authors:  Pallavi Chaturvedi; Ajay P Singh; Surinder K Batra
Journal:  FASEB J       Date:  2007-11-16       Impact factor: 5.191

Review 4.  Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer.

Authors:  Juliette Thariat; Luka Milas; K Kian Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-15       Impact factor: 7.038

5.  erbB3 is an active tyrosine kinase capable of homo- and heterointeractions.

Authors:  Mara P Steinkamp; Shalini T Low-Nam; Shujie Yang; Keith A Lidke; Diane S Lidke; Bridget S Wilson
Journal:  Mol Cell Biol       Date:  2013-12-30       Impact factor: 4.272

6.  IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistance.

Authors:  Colin D White; Zhigang Li; Deborah A Dillon; David B Sacks
Journal:  J Biol Chem       Date:  2011-07-01       Impact factor: 5.157

7.  A mathematical model for BRASSINOSTEROID INSENSITIVE1-mediated signaling in root growth and hypocotyl elongation.

Authors:  G Wilma van Esse; Simon van Mourik; Hans Stigter; Colette A ten Hove; Jaap Molenaar; Sacco C de Vries
Journal:  Plant Physiol       Date:  2012-07-16       Impact factor: 8.340

8.  Quantification of the brassinosteroid insensitive1 receptor in planta.

Authors:  G Wilma van Esse; Adrie H Westphal; Ramya Preethi Surendran; Catherine Albrecht; Boudewijn van Veen; Jan Willem Borst; Sacco C de Vries
Journal:  Plant Physiol       Date:  2011-05-26       Impact factor: 8.340

9.  CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications.

Authors:  Anke Steinmetz; François Vallée; Christian Beil; Christian Lange; Nicolas Baurin; Jochen Beninga; Cécile Capdevila; Carsten Corvey; Alain Dupuy; Paul Ferrari; Alexey Rak; Peter Wonerow; Jochen Kruip; Vincent Mikol; Ercole Rao
Journal:  MAbs       Date:  2016-03-16       Impact factor: 5.857

10.  MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells.

Authors:  Pallavi Chaturvedi; Ajay P Singh; Subhankar Chakraborty; Subhash C Chauhan; Sangeeta Bafna; Jane L Meza; Pankaj K Singh; Michael A Hollingsworth; Parmender P Mehta; Surinder K Batra
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.